Advanced Search

Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2011 February;102(1) > Minerva Medica 2011 February;102(1):79-92



A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

Frequency: Bi-Monthly

ISSN 0026-4806

Online ISSN 1827-1669


Minerva Medica 2011 February;102(1):79-92


Mucositis in oncohematology

Niscola P. 1, Tendas A. 1, Giovannini M. 1, Scaramucci L. 1, De Sanctis V. 2, Cupelli L. 1, De Fabritiis P. 1

1 Unità Operativa di Ematologia, Ospedale Sant’Eugenio, Roma, Italia;
2 Dipartimento di Radioterapia, Università “La Sapienza”, Roma, Italia

Mucositis is the result of the cytotoxic effects of many treatments given for hematological malignancies (HMs); it represents a major source of potentially devastating clinical complications and portrays negative consequences on the patient’s management, such as a longer hospitalization, the need of analgesic and total parenteral nutrition use, and increased costs. The available measures for the prevention and treatment of mucositis have been substantially palliative, being limited to the control of pain, infection, bleeding and nutrition. However, in the last decade, a better insight into the complex pathogenesis of MBI has led to the development of novel therapeutic options, such as palifermin, which can provide tools potentially allowing a targeted approach to mucositis.

language: Italian


top of page